What are the side effects of trametinib?
More common
- Burning, itching, and pain in hairy areas, pus at the root of the hair.
- canker sores.
- change in taste.
- dry eyes.
- dry skin.
- itching, pain, redness, swelling, tenderness, or warmth on the skin.
- loosening of the fingernails.
- loss of taste.
Is trametinib cytotoxic?
Although trametinib is an effective drug that suppresses the growth of colon cancer cells, it did not achieve adequate cytotoxicity and inhibit the over-expression of ERRα induced by EGF.
Is trametinib a chemotherapy drug?
Trametinib is the generic name for the trade name chemotherapy drug Mekinist. In some cases, health care professionals may use the trade name Mekinist when referring to the generic name trametinib. Drug type: Trametinib is a targeted therapy.
Does trametinib cause weight gain?
Trametinib may cause heart problems, including heart failure. Check with your doctor right away if you have chest pain, decreased urine output, an uneven heartbeat, swelling of the face, fingers, feet, or lower legs, troubled breathing, or rapid weight gain while using trametinib.
What is the half life of trametinib?
The effective half-life of trametinib was about 4 days. At the recommended phase 2 dose, the exposure profile of the drug showed low interpatient variability and a small peak:trough ratio of 1·81.
Is Mekinist a chemo drug?
Mekinist is the trade name for the generic chemotherapy drug trametinib. In some cases, health care professionals may use the generic name trametinib when referring to the trade name Mekinist.
How long do you take trametinib?
For advanced cancer you take dabrafenib and trametinib for as long as they are working and the side effects aren’t too bad. If you’re having this combination of drugs to prevent melanoma skin cancer coming back after surgery, you take them for up to 12 months.
What kind of drug is trametinib?
Trametinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
When was trametinib approved by the FDA?
FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600E or V600K mutations. On April 30, 2018, the Food and Drug Administration granted regular approval to dabrafenib (TAFINLAR, Novartis Pharmaceuticals Corp.) and trametinib (MEKINIST, Novartis Pharmaceuticals Corp.)
